Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: ABT.NYSE
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Abbott Laboratories (ABT) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

BUY

$115

+11.7%+13.2% incl. dividends

2031

5-Year

BUY

$170

+65.7%+77.6% incl. dividends

Published batch insight

Medical Device Compounding Unlocks Durable Value Beneath Litigation and Leverage Overhangs

Independent analysis reveals high consensus that accelerating continuous glucose monitoring and transcatheter cardiovascular interventions drive durable organic compounding. While headline infant formula litigation and debt-funded oncology integration temporarily compress reported margins, robust free cash conversion insulates dividend growth and funds deleveraging against persistent macroeconomic discount-rate headwinds.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Michael Burry (Vulture), Universal Investor (Polymath), Elon Musk (Visionary), Warren Buffett (Value Purist), J.P. Morgan (Titan), Superintelligence (Anthropologist), Machiavelli (Insider), Sherlock Holmes (Whistleblower), Ray Dalio (Strategist). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Abbott Laboratories at the forecast anchor (2026-09-18): $17,759 in five years versus $13,892 for S&P 500 benchmark.

Abbott Laboratories · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 1.4% net dividend yield for Abbott Laboratories.

Figure: Five-year synthesized consensus value path for Abbott Laboratories compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 102.61 USD1-year price return: +11.66%5-year price return: +65.67%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	105.06	+2.39%	+2.39%	Third-quarter results validate oncology diagnostics integration while infant formula settlement finalization bounds headline liabilities. Resilient FreeStyle Libre sensor volume growth offsets macro discount-rate pressures, prompting initial valuation multiple stabilization from deeply depressed sentiment levels.
Q1 2027	107.92	+2.72%	+5.18%	Full-year 2026 reporting confirms operating cash generation approaching eight billion dollars, meeting guidance expectations. Management's 2027 outlook highlights steady continuous glucose monitoring adoption and initial oncology commercial cross-selling, reassuring institutional allocators regarding capital allocation discipline.
Q2 2027	111.68	+3.48%	+8.84%	First anniversary of the oncology acquisition establishes clean comparable sales growth benchmarks. Accelerating TriClip procedural volumes and European pulsed-field ablation commercialization cushion against higher sovereign bond yields, sustaining steady operational earnings compounding across core divisions.
Q3 2027	114.58	+2.60%	+11.66%	Mid-year consolidation reflects seasonal procedure moderation and persistent hospital procurement scrutiny. Stable recurring reagent testing on Alinity systems and expanding Libre Duo distribution prevent valuation slippage, anchoring equity performance during broader macroeconomic growth deceleration.
Q4 2027	118.62	+3.53%	+15.61%	Announcement of the fifty-fifth consecutive annual dividend increase reinforces dividend aristocrat credibility. Cash generation funds visible acquisition debt retirement, reducing perceived balance-sheet leverage risk as favorable appellate rulings begin trimming residual infant formula litigation exposure.
Q1 2028	122.56	+3.32%	+19.44%	Fiscal 2027 results showcase operating margins expanding toward nineteen percent as oncology purchase-accounting dilution begins to abate. Strong consumable sensor replenishment and steady emerging-market branded generic drug demand drive solid adjusted earnings per share progression.
Q2 2028	126.45	+3.17%	+23.23%	Pulsed-field ablation systems capture domestic electrophysiology market share from legacy radiofrequency competitors. High attachment rates for cardiovascular consumables bolster device division gross margins, counteracting persistent international volume-based procurement pricing pressures across European and Asian hospitals.
Q3 2028	128.27	+1.44%	+25.01%	Mid-year earnings demonstrate accelerating cash conversion as twelve-month free cash flow reaches nine billion dollars. Management continues prioritizing balance-sheet deleveraging over aggressive buybacks, building institutional confidence in structural solvency and earnings quality amidst tight monetary policy.
Q4 2028	132.58	+3.36%	+29.21%	Formalization of additional infant formula settlement inventories clears headline legal uncertainty, unlocking modest multiple expansion. Consumer metabolic biowearable rollouts broaden non-diabetic recurring revenue streams, positioning the business for sustained mid-single-digit organic top-line compounding into year-end.
Q1 2029	135.49	+2.20%	+32.05%	Full-year 2028 reporting confirms net leverage contracting below two times EBITDA. Restored balance-sheet flexibility allows leadership to reactivate selective share repurchases, supporting per-share intrinsic value growth as core laboratory diagnostic system placements sustain recurring reagent pull-through.
Q2 2029	139.38	+2.87%	+35.84%	Next-generation continuous glucose-ketone dual sensors gain European commercial traction, defending market share against specialized medtech rivals. Favorable reimbursement coverage for intensive insulin cohorts expands addressable sensor volumes, driving mid-single-digit quarterly equity appreciation on high gross margins.
Q3 2029	142.65	+2.34%	+39.02%	Late-summer healthcare utilization trends remain solid across North American hospital networks. While tariff frictions and foreign exchange translation create modest margin drag, Abbott's non-discretionary clinical portfolio delivers dependable defensive earnings stability relative to economically sensitive sectors.
Q4 2029	147.01	+3.06%	+43.27%	Annual free cash flow surpasses ten billion dollars, funding accelerated open-market share retirements and another dividend increase. Tricuspid valve repair adoption expands across aging demographics, reinforcing structural heart leadership and elevating corporate operating margins toward twenty percent.
Q1 2030	150.70	+2.51%	+46.87%	Fiscal 2029 financials confirm consistent seven percent organic revenue compounding across all four pillars. Oncology diagnostic screening achieves widespread routine outpatient adoption, validating multi-year merger synergies and prompting equity research analysts to lift long-term cash flow forecasts.
Q2 2030	153.59	+1.92%	+49.69%	Global adoption of consumer metabolic wellness monitors scales manufacturing efficiencies, lowering unit sensor production costs. Automated sensor assembly lines protect consolidated gross margins against payer price resistance, ensuring dependable mid-single-digit operating income expansion across international commercial channels.
Q3 2030	155.90	+1.50%	+51.93%	Late-cycle macroeconomic deceleration prompts broad institutional capital rotation toward defensive healthcare stalwarts. Abbott's low financial leverage, pristine credit rating, and non-cyclical chronic disease management portfolio command an enduring safe-haven bid across sovereign wealth and pension funds.
Q4 2030	159.70	+2.44%	+55.64%	Management announces its fifty-eighth consecutive annual dividend hike alongside expanded share buybacks. Disciplined manufacturing execution across cardiovascular and diagnostic divisions shields profitability from raw-material inflation, securing dependable quarterly price performance into the close of the fiscal year.
Q1 2031	163.33	+2.27%	+59.17%	Full-year 2030 results demonstrate normalized adjusted earnings per share crossing eight dollars on sustained operational discipline. The market fully prices Abbott's transformed oncology diagnostics and diabetes care platforms, completing multiple rerating toward historical peer averages as legal clouds evaporate.
Q2 2031	166.74	+2.09%	+62.50%	Next-generation continuous molecular monitoring and leadless cardiac pacing pipelines achieve key clinical milestones, reinforcing pipeline visibility into the mid-2030s. Strong cash conversion funds ongoing internal innovation while supporting consistent capital returns to long-term shareholders.
Q3 2031	169.99	+1.95%	+65.67%	The five-year forecast culminates with Abbott firmly established as a premier diversified medtech and diagnostics compounder. Normalized earnings power, extinguished litigation overhangs, and successful post-merger integration deliver resilient total shareholder returns across shifting macroeconomic and interest-rate regimes.

A pronounced optical disconnect masks underlying operational resilience. While headline earnings are depressed by purchase-accounting amortization from the recent multi-billion-dollar oncology acquisition and ongoing legal provisions, core organic revenue is compounding steadily. Dominant market positions in continuous glucose monitoring and transcatheter cardiovascular interventions generate dependable, high-margin consumable streams that insulate operating cash flows. The primary valuation tension centers on elevated post-acquisition leverage and headline tort risks against an unappreciated recurring cash flow yield. As integration expenses lap and master settlements ring-fence legacy liabilities, operating leverage will drive normalized multiple expansion across the multi-year investment horizon.

Key insights

Consumable sensor replenishment and structural heart procedure volumes provide recurring annuity revenues that decouple enterprise operating cash flows from cyclical hospital equipment spending.
Substantial post-transaction balance sheet debt prioritizes early operational cash flow toward deleveraging, subordinating discretionary share repurchases until gross leverage ratios normalize below target.
Structured legal settlements transform existential mass-tort tail risks into ring-fenced, predictable corporate liabilities that are comfortably absorbable through ongoing organic free cash generation.

Deep Dive

Market consensus currently discounts the company as an encumbered, sluggish healthcare conglomerate trapped between unresolved infant formula mass-tort liabilities, post-pandemic diagnostic volume erosion, and balance-sheet indigestion following its multi-billion-dollar oncology acquisition. Investors fixate on backward-looking GAAP earnings volatility and higher benchmark interest rates, assuming regulatory scrutiny and elevated leverage permanently cap valuation multiples and restrict near-term total returns.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd materially underestimates value through underpricing caused by confusing transitory accounting charges with structural business impairment. Trailing reported GAAP earnings reflect non-cash acquisition amortization and non-operating legal reserves, masking underlying operational resilience evidenced by nearly eight billion dollars in normalized free cash flow. Investors overlook that double-digit expansion in continuous glucose monitoring and transcatheter cardiovascular interventions delivers high-margin recurring cash flows. While debt reduction will constrain immediate share repurchases, the resulting cash conversion justifies a meaningful valuation rerating.

Repricing catalyst

Convergence will be triggered by sequential quarterly earnings reports demonstrating oncology diagnostics margin accretion and double-digit medical device revenue expansion, alongside formal judicial execution of infant formula settlement frameworks through late 2026 and 2027. Demonstrating clean organic comparable sales growth approaching seven percent while visibly reducing net debt will prove that acquisition leverage and legal overhangs are contained, prompting institutional allocators to reprice shares toward historical medtech valuation benchmarks.

Published consensus context

Macro regime alignment

The macroeconomic setup presents a mixed backdrop for enterprise valuation. Restrictive monetary policy and elevated sovereign bond yields enforce higher hurdle discount rates across large-cap healthcare assets. However, non-discretionary clinical demand, recurring medical consumable utilization, and robust organic cash generation provide exceptional defensive resilience, turning late-cycle economic deceleration into a relative operational and balance-sheet advantage.

Published consensus context

Advisor disagreement

The central debate across reports centers on whether Abbott's multi-billion-dollar oncology acquisition enhances long-term compounding or introduces dangerous debt overhang into an elevated interest-rate regime. Bullish analyses argue that Cologuard's established clinical guideline positioning and FreeStyle Libre's consumable expansion will rapidly de-lever the balance sheet while driving operating margins toward twenty percent. Conversely, skeptical viewpoints contend that twenty billion dollars in new debt and persistent infant formula litigation tail risks will constrain capital flexibility and freeze multiple expansion. Observable net debt reduction and comparable diagnostics growth across 2027 earnings reports will definitively resolve this debate.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Continuous Glucose Monitoring Secular Scaling: Expanding beyond intensive diabetes care into basal and pre-diabetic populations drives recurring sensor replenishment, making patient utilization an annuity-like revenue stream. Supported by automated manufacturing and over-the-counter wellness platforms, this high-margin consumable ecosystem insulates operating profits from broader economic downturns, sustaining high-single-digit organic growth and expanding consolidated corporate gross margins. Expected impact: +24%.
Structural Heart and Electrophysiology Expansion: Proprietary transcatheter tricuspid and mitral valve repair platforms alongside pulsed-field ablation catheter rollouts command formidable clinical and regulatory switching barriers. High-acuity surgical volumes remain thoroughly insulated from macroeconomic fluctuations, enabling Abbott to capture premium hospital reimbursement. This procedural acceleration expands medical device operating margins, converting volume gains into durable, multi-year operating cash flow growth. Expected impact: +18%.
Oncology Diagnostic Screening Synergies: Integrating established non-invasive colorectal cancer screening assets into Abbott's ubiquitous global hospital and laboratory distribution channels unlocks substantial commercial scale. As initial acquisition-related financing dilution and purchase-accounting amortizations lap through 2027, cross-selling across primary-care networks accelerates recurring testing volumes, delivering high-margin operational leverage that directly enhances diagnostic segment earnings. Expected impact: +16%.
Emerging Market Branded Generics Compounding: The Established Pharmaceuticals business leverages deeply entrenched local distribution networks across demographic growth corridors in Latin America and Asia, selling trusted off-patent medicines directly into cash-pay markets. Bypassing Western reimbursement price controls and patent cliff vulnerabilities, this localized operational engine generates reliable high-single-digit volume compounding and defensive, countercyclical free cash flow. Expected impact: +11%.

Top frictions and headwinds

Acquisition Debt Servicing and Deleveraging: Financing the twenty-one-billion-dollar oncology transaction elevated gross debt obligations past thirty-two billion dollars under a restrictive monetary backdrop. Heightened annual interest expense and priority debt paydown temporarily divert operating cash flow away from discretionary share repurchases. Until gross leverage normalizes toward historical levels, elevated capital absorption constrains per-share earnings growth and caps multiple expansion. Expected impact: -10%.
Preterm Infant Formula Residual Litigation: Although landmark master settlements bound approximately two thousand state claims, thousands of residual infant formula lawsuits remain pending in federal and state courts. Ongoing defense expenditures, compliance oversight, and the persistent potential for adverse trial verdicts impose a lingering sentiment overhang, requiring conservative balance-sheet contingency reserves that depress headline reported net earnings. Expected impact: -9%.
Restrictive Cost of Capital Regime: Persistent benchmark sovereign yields hovering near five percent enforce higher hurdle discount rates across mega-cap defensive healthcare equities. Tight monetary policy raises debt refinancing costs and strains non-profit hospital capital budgets, lengthening equipment replacement cycles for automated diagnostic instrumentation and compressing price-to-earnings multiples across diversified medtech peers. Expected impact: -8%.
Reimbursement Austerity and Pricing Resistance: Intensifying price competition in continuous glucose monitoring alongside international volume-based procurement mandates in China and Europe restricts realized unit prices. Payer bargaining and mandatory tender discounts prevent procedural volume gains from flowing fully into operating profits, diluting incremental gross margins across mature diagnostics, nutrition, and cardiovascular product lines. Expected impact: -7%.

Tail risks

Uncontained Multidistrict Tort Settlement Contagion: State appellate courts invalidate master settlement frameworks while adverse bellwether trials assess multi-billion-dollar punitive damages across unreserved infant formula claims through 2028. The resulting liability pool exceeding five billion dollars would deplete corporate cash, halt share repurchases, threaten credit metrics, and force substantial debt issuance during an elevated rate environment, causing severe institutional equity liquidation. Probability: +24%. Expected impact: -26%.
Severe Biosensor Quality and Recall Shock: A catastrophic manufacturing defect or FDA distribution restriction compromises flagship continuous glucose monitor production by late 2027, triggering a mandatory global Class I recall. Extended supply suspensions and reputational impairment would force patients toward competing platforms, erasing billions in high-margin consumable sensor sales and permanently depressing Abbott's primary organic growth engine and enterprise valuation multiple. Probability: +18%. Expected impact: -24%.

Tail opportunities

Universal Continuous Glucose Monitoring Reimbursement: Centers for Medicare & Medicaid Services and commercial insurers formally expand coverage mandates to include all thirty million non-insulin Type 2 diabetes patients by 2028. Driven by real-world clinical outcomes proving cardiovascular event reductions, FreeStyle Libre addressable domestic volume would triple, injecting over two billion dollars in high-margin recurring operating income and sparking an aggressive institutional multiple rerating. Probability: +35%. Expected impact: +23%.
Comprehensive Legal Preemption Verdict Resolution: Federal appellate courts or statutory reform establish definitive federal preemption across all pending state-level preterm infant formula claims, citing FDA-mandated nutritional standards. Enacted by late 2027, this judicial breakthrough extinguishes residual mass-tort liabilities overnight without additional multibillion-dollar cash reserves, immediately releasing trapped balance-sheet liquidity and triggering a rapid valuation multiple expansion toward historic medtech leader premiums. Probability: +32%. Expected impact: +19%.

What to monitor

Thesis watchpoints

-- FreeStyle Libre quarterly global sales sustaining constant-currency revenue growth above ten percent through late 2027 confirms core medical device durability.

Key insights

Consolidated operating margins remaining below seventeen percent across two consecutive quarters in 2027 signals severe procurement resistance or integration friction.
Cumulative unreserved infant formula trial verdicts or settlement accruals exceeding two billion dollars by late 2027 necessitates capital allocation reassessment.

Company Financial Analysis

Abbott Laboratories Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Abbott's recent financial headlines look deceptive at first glance. Reported accounting profit fell sharply in mid-2026, but this drop was caused by non-operating legal settlement reserves and purchase-accounting charges from acquiring Exact Sciences rather than slowing customer sales. In fact, underlying business revenue climbed to forty-six point six billion dollars over the trailing twelve months, powered by resilient high-single-digit growth across medical devices and branded generic medicines. The true operational health appears in cash generation. Abbott produced nearly eight billion dollars in trailing free cash flow, showing that its core commercial engine remains exceptionally profitable. As acquisition integration charges fade, headline earnings will re-align with cash flows, supporting steady long-term compounding.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 44.3B	USD 6.5B	USD 7.4B
2024	USD 42B	USD 13.4B	USD 6.4B
2023	USD 40.1B	USD 5.7B	USD 5.1B
2022	USD 43.7B	USD 6.9B	USD 7.8B
2021	USD 43.1B	USD 7.1B	USD 8.6B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	33.6x	TTM	Native	USD / USD
2024	14.7x	TTM	Native	USD / USD
2023	33.6x	TTM	Native	USD / USD
2022	27.8x	Annual	Native	USD / USD
2021	35.5x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Abbott's profitability reveals an underlying improvement in product quality. Adjusted gross margins widened toward fifty-eight percent in mid-2026, driven by a favorable mix shift toward high-margin medical devices, glucose sensors, and precision oncology screening. These proprietary medical products carry strong pricing power, effectively counteracting raw-material inflation, hospital budget constraints, and international tariff headwinds. Although reported net income margins dipped temporarily due to acquisition financing and legal accruals, operating margins are positioned to recover toward twenty percent. As one-off merger expenses subside and automated manufacturing lowers unit sensor costs, operational leverage will drive accelerated profit growth across the five-year investment horizon.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 8B	18.2%	14.7%
2024	USD 6.8B	16.3%	31.9%
2023	USD 6.4B	16.0%	14.3%
2022	USD 8.4B	19.2%	15.9%
2021	USD 9.2B	21.4%	16.4%

Balance sheet and leverage

AI Review

Abbott's balance sheet underwent a major shift in 2026 following the Exact Sciences acquisition, which was funded through a twenty-billion-dollar debt offering. Consequently, gross debt expanded to approximately thirty-two point six billion dollars by mid-year. While headline leverage ratios increased, the company's financial foundation remains solid, supported by fifty-two billion dollars in shareholder equity and strong operating liquidity. The critical priority for cash flow over the next two years is debt reduction rather than aggressive stock buybacks. Because annual free cash flow approaches eight billion dollars, Abbott can comfortably service its debt obligations, fund ongoing legal settlements, and protect its fifty-four-year dividend growth streak.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 15.1B	USD 8.9B	USD 6.5B net debt	1.58x
2024	USD 15.3B	USD 8B	USD 7.7B net debt	1.67x
2023	USD 15.9B	USD 7.3B	USD 9B net debt	1.64x
2022	USD 17.9B	USD 10.2B	USD 8.1B net debt	1.63x
2021	USD 19.3B	USD 10.2B	USD 9.5B net debt	1.85x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management has demonstrated careful capital discipline in its physical facilities. Annual capital expenditures have consistently averaged approximately five percent of revenue, totaling just over two billion dollars. Reinvestment focuses strictly on high-return manufacturing automation for continuous glucose monitors and cleanrooms for structural heart devices, avoiding wasteful factory overbuilding. The company's major strategic bet was inorganic: spending twenty-one billion dollars in March 2026 to acquire Exact Sciences. This transformative cancer-screening investment commits substantial capital, but relies on existing hospital distribution rather than heavy ongoing factory expansion. This targeted capital posture preserves strong cash conversion while building intellectual property moats.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 2.2B	USD 3B
2024	USD 2.2B	USD 2.8B
2023	USD 2.2B	USD 2.7B
2022	USD 1.8B	USD 2.9B
2021	USD 1.9B	USD 2.7B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	BUY	221	+13.5%	Not available	ORIGINAL
5Y	BUY	223	+81%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	99.53	105.4	108.77	14
+6M	March 18, 2027	97.54	108.35	114.2	14
+9M	June 18, 2027	98.52	111.95	118.77	14
+1Y	September 18, 2027	96.55	114.88	124.71	14
+15M	December 18, 2027	98.48	118.93	129.7	14
+18M	March 18, 2028	99.46	122.99	136.19	14
+21M	June 18, 2028	101.45	126.88	141.63	14
+2Y	September 18, 2028	100.44	129.07	145.88	14
+27M	December 18, 2028	102.45	133.35	151.72	14
+30M	March 18, 2029	103.47	137.01	159.3	14
+33M	June 18, 2029	103.47	140.88	162.49	14
+3Y	September 18, 2029	104.5	144.19	168.99	14
+39M	December 18, 2029	106.59	148.65	174.06	14
+42M	March 18, 2030	105.53	152.65	181.02	14
+45M	June 18, 2030	107.64	156.11	186.45	14
+4Y	September 18, 2030	107.64	158.9	192.04	14
+51M	December 18, 2030	109.79	162.81	197.81	14
+54M	March 18, 2031	110.89	166.75	201.76	14
+57M	June 18, 2031	109.78	170.09	205.8	14
+5Y	September 18, 2031	110.88	173.62	209.91	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The common pattern across reports identifies Abbott as an entrenched healthcare compounder whose core operational power is obscured by transient infant formula litigation and debt from the March 2026 oncology acquisition. However, significant divergence emerges in balance-sheet modeling: several reports rely on stale year-end 2025 leverage metrics, failing to reflect the twenty-billion-dollar debt issuance disclosed in the June 2026 Form 10-Q. Highest weight is allocated to independent analyses that rigorously incorporate verified SEC filings, reconciling acquisition dilution, realistic post-deal net debt of twenty-seven billion dollars, and residual mass-tort exposure covering thousands of infants. Reports that omit the transaction entirely or extrapolate multiple reratings without modeling debt service receive lower allocations. The credible contrarian case highlighting discount-rate gravity under persistent benchmark yields is preserved to restrain aggressive valuation assumptions. Unresolved litigation appellate timelines and continuous sensor pricing competition ultimately govern relative weighting.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight15.0/100

Exhibits superior research quality, citing verified SEC filings, June 2026 balance-sheet data showing thirty-two billion dollars in gross debt, FDA clearances, and oncology screening guidelines. Models realistic quarterly drawdowns and cautious deleveraging constraints. Assigned the highest weight of 0.15 for unmatched empirical rigor.

AI RESEARCHER

Universal Investor AI

The Polymath

Opus 5

Weight14.0/100

Provides exceptional empirical analysis of Q2 2026 results, distinguishing reported from comparable growth and detailing Exact Sciences financing notes. Accurately scopes the residual twelve-thousand-infant litigation docket and decelerating sensor growth. Assigned a substantial 0.14 weight for rigorous financial forensics and realistic path constraints.

AI RESEARCHER

Michael Burry AI

The Vulture

Gemini 3.8 Flash

Weight9.0/100

Offers sharp forensic analysis of infant formula litigation, accurately identifying the August and September 2026 settlements as ring-fencing events. Incorporates Exact Sciences screening synergies and realistic free cash flow yields. Assigned a 0.09 weight for rigorous legal risk bounding and sound cash conversion metrics.

AI RESEARCHER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight8.0/100

Synthesizes Exact Sciences integration, Libre Duo rollouts, and infant formula legal progress into a balanced seven-percent organic compounding scenario. Correctly captures integration friction while modeling realistic operating margin progression toward twenty percent. Assigned an 0.08 weight for thorough multi-factor integration and causal consistency.

AI RESEARCHER

Sherlock Holmes AI

The Whistleblower

Gemini 3.8 Flash

Weight8.0/100

Demonstrates strong forensic grounding, evaluating the 670-million-dollar infant formula settlement alongside DOJ resolutions and post-acquisition amortization. Correctly highlights refinancing hurdles under tight monetary policy and Volt PFA rollout traction. Assigned an 0.08 weight for detailed legal and operational reconciliation.

AI RESEARCHER

Ray Dalio AI

The Strategist

Gemini 3.8 Flash

Weight7.0/100

Provides a coherent macro-defensive compounding framework, highlighting FreeStyle Libre scaling and Exact Sciences oncology synergies. However, it relies on older pre-acquisition leverage figures and underestimates the initial debt service drag. Assigned a 0.07 weight reflecting solid operational insight tempered by loose balance-sheet assumptions.

AI RESEARCHER

J.P. Morgan AI

The Titan

Gemini 3.8 Flash

Weight7.0/100

Constructs a detailed institutional thesis highlighting cardiovascular device leadership and oncology screening integration. However, its forecasted multiple expansion to twenty-four times forward earnings in an elevated rate regime is overly aggressive. Assigned a 0.07 weight for strong operational analysis tempered by optimistic valuation assumptions.

AI RESEARCHER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight6.0/100

Effectively combines Exact Sciences integration, electrophysiology adoption, and litigation de-risking within an owner-earnings framework. Models steady operating margin expansion toward twenty percent while acknowledging tariff and pricing frictions, justifying a 0.06 weight for solid causal consistency and realistic compounding.

AI RESEARCHER

Niccolo Machiavelli AI

The Insider

Gemini 3.8 Flash

Weight5.0/100

Contributes distinctive insights into government WIC infant formula procurement hegemony and legal settlements, but omits the oncology acquisition and its debt burden. Assigned a 0.05 weight; its unique institutional analysis is valuable but bounded by capital structure blind spots.

AI RESEARCHER

Elon Musk AI

The Visionary

Gemini 3.8 Flash

Weight5.0/100

Supplies a valuable contrarian reality check on discount-rate gravity, tech disruption risks, and multiple compression under five-percent Treasury yields. However, it relies on optical trailing P/E distortions and omits the Exact acquisition, receiving a 0.05 weight for useful risk calibration.

AI THINKER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight4.0/100

Presents strong biological demand framing for diabetes care and structural heart therapies. However, it completely omits the twenty-one-billion-dollar Exact Sciences acquisition and subsequent twenty-billion-dollar debt issuance, using outdated balance-sheet leverage metrics. Assigned a reduced 0.04 weight due to this major material omission.

AI THINKER

Universal Investor AI

The Polymath

Gemini 3.8 Flash

Weight4.0/100

Accurately assesses core medical device momentum and Q2 2026 revenue trends, but fails to account for the Exact Sciences merger and its debt financing. Models a more conservative path that correctly captures litigation uncertainty, earning a 0.04 weight due to stale capital structure inputs.

AI THINKER

Warren Buffett AI

The Value Seeker

Gemini 3.8 Flash

Weight4.0/100

Articulates a classic economic moat thesis around FreeStyle Libre and structural heart implants, but completely ignores the March 2026 Exact Sciences acquisition and twenty-billion-dollar debt issuance. Stale balance-sheet inputs limit its forward utility, justifying a reduced 0.04 weight despite sound qualitative moat reasoning.

AI RESEARCHER

Superintelligence AI

The Anthropologist

Gemini 3.8 Flash

Weight4.0/100

Develops an insightful human-telemetry narrative around FreeStyle Libre and structural heart repair, but completely overlooks the twenty-one-billion-dollar Exact Sciences transaction. Its reliance on pre-acquisition debt metrics and aggressive valuation targets requires downweighting to 0.04 due to incomplete material information.

Skip to references

Research Provenance

References & Context

This Abbott Laboratories consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 126 deduplicated sources retained for this batch.

01Device Classification Under Section 513(f)(2)(De Novo)accessdata.fda.gov
02Article - Glucose Monitor - Policy Article (A52464)cms.gov
03Abbott Diabetes Care, Inc. - 722046 - 01/23/2026 | FDAfda.gov
04Federal Reserve Board - Federal Reserve issues FOMC statementfederalreserve.gov
05ABBOTT LABORATORIES - Form 8-K - FY2026sec.gov
06abt-20251231sec.gov
07abt-20260630sec.gov
08www.sec.govsec.gov
09www.sec.govsec.gov
10Abbott Price Prediction: Where Will the Stock Be in 2027 - 24/7 Wall St.247wallst.com
11Buy, Hold, or Sell: Tech Compression Dragged Abbott Labs Under $91, but 1 Massive Diabetes Catalyst Makes It a Screaming Buy - 24/7 Wall St.247wallst.com
12Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love - 24/7 Wall St.247wallst.com
13Abbott acquisition of Exact Sciences set to close on March 23, 2026 - Mar 20, 2026abbott.mediaroom.com
14Abbott completes acquisition of Exact Sciences - Mar 23, 2026abbott.mediaroom.com
15Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance - Jul 16, 2026abbott.mediaroom.com

And 111 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.